
|Videos|December 17, 2020
Decline seen in Medicare reimbursement for men's health procedures
Author(s)Urology Times staff
Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss trends in reimbursement for men's health procedures from 2002 to 2020.
Advertisement
In this interview, Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss findings from their study, Decreasing Medicare Reimbursement for Men's Health Procedures: 2002-2020, which was presented at the 21st annual fall scientific meeting of Sexual Medicine Society of North America. Edmonds is a 4th year medical student at Mayo Clinic in Phoenix, Arizona, and Köhler is director of men’s health at Mayo Clinic, in Rochester, Minnesota.
Advertisement
Related to this article

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5

